Acne and Testosterone — What's the Real Connection?

In men, testosterone is produced mainly in the testes, under control of the hypothalamic-pituitary-gonadal axis: the hypothalamus releases GnRH, which stimulates the pituitary to produce LH and FSH, and LH in turn stimulates Leydig cells in the testes to synthesize testosterone. Part of the hormone circulates in blood bound to proteins (mainly SHBG), and part remains free and biologically active — it's this free testosterone, not total, that matters more for how much hormone actually reaches tissues, including the skin.

A key point we'll return to throughout this article: how much testosterone circulates in your blood tells you surprisingly little about what's happening in a specific sebaceous gland on your face. Blood delivers the hormone to skin, but what happens to it there — whether it gets converted to a stronger form, whether it effectively binds the receptor — depends on local, tissue-level mechanisms that differ substantially between people, and even between different skin areas of the same person.

Within the sebaceous gland itself, in cells called sebocytes, the enzyme 5-alpha-reductase type 1 is present. Its job is converting testosterone into dihydrotestosterone (DHT) — a hormone with several times stronger affinity for the androgen receptor than testosterone itself. This conversion happens locally, on site, in the skin — not in the liver or some distant organ — which means its intensity depends on how much active 5-alpha-reductase a given person has in a given skin area, not solely on the concentration of testosterone in the blood reaching that spot.

This local enzymatic activity isn't uniform. In acne-affected skin, 5-alpha-reductase activity and the rate of testosterone-to-DHT conversion are many times higher than in healthy skin on the same person — which partly explains why the face, back, and chest (areas with naturally the highest density of sebaceous glands) are far more prone to acne than, say, forearm skin, despite an identical testosterone level in the blood supplying the whole body.

Once formed in the sebocyte, DHT binds the androgen receptor — a protein located in the cell's cytoplasm. The hormone-receptor complex then moves into the cell nucleus, where it acts like a switch: turning on specific genes responsible for sebocyte maturation and lipid production. It's this step — binding the receptor and activating gene transcription — that actually changes the cell's behavior, not merely the hormone's presence nearby.

A key practical consequence: the sensitivity and number of androgen receptors vary genetically between people, independent of hormone level. Two people with identical testosterone and DHT blood concentrations can have a completely different cellular response in the sebaceous gland if their receptors differ in sensitivity. This is exactly why blood testosterone level is a poor predictor of acne severity — a thread we develop separately in the article 'Does High Testosterone Cause Acne?', dedicated to debunking the myth of a linear relationship between hormone level and skin severity.

A receptor-stimulated sebocyte produces more sebum with an altered, more pro-inflammatory composition. At the same time, androgens accelerate keratinization of the epithelium lining the follicle opening — skin cells shed abnormally and stick together instead of flaking off freely. The combination of these two effects — more, denser sebum plus a narrowed, partly blocked follicle opening — leads to a microcomedone: the earliest, invisible-to-the-eye acne lesion.

A blocked, lipid-rich hair follicle becomes an anaerobic environment favorable to the growth of Cutibacterium acnes — a natural skin resident that, in excess sebum, begins to multiply rapidly, breaking lipids down into irritating free fatty acids and activating the local immune system. It's this inflammatory response, not the follicle blockage itself, that turns an invisible microcomedone into a visible, often painful papule or pustule. The entire chain — testosterone → conversion to DHT → androgen receptor → more and different sebum → blocked follicle → bacterial proliferation → inflammation — is today recognized as the central pathophysiological mechanism of androgen-dependent acne, regardless of whether the excess androgen signal comes from natural hormonal fluctuation or another source.

It's worth clearly emphasizing something easy to miss in oversimplified explanations: each of the four steps described above — blood hormone level, local conversion activity to DHT, androgen receptor sensitivity, and individual sebocyte reactivity — can vary between people independently of the others. This means a man with testosterone at the lower end of the normal range can have severe acne if his local DHT conversion or receptor sensitivity is high, while a man with testosterone at the upper end of the normal range can have clear skin if those two parameters are low for him.

Understanding the full chain has concrete practical value: it shows why effective treatment of androgen-dependent acne rarely involves trying to lower blood testosterone (which in men is complex anyway and carries its own side effects), and much more often involves breaking the chain at its later, more accessible links: normalizing follicular keratinization (retinoids), limiting bacterial growth (benzoyl peroxide, antibiotics), and reducing inflammation. That's why dermatological treatment of hormonal acne works for the vast majority of patients without needing to intervene in hormone balance.

Testosterone is a real, well-documented part of the acne mechanism — but it acts through a multi-step chain in which the hormone's blood level is only the first, and not necessarily the most important, link. Local conversion to DHT and androgen receptor sensitivity in the skin often determine acne severity more strongly than the blood test result. This distinction has real clinical relevance: it explains why two people with identical testosterone can have completely different skin, and why effective treatment rarely involves trying to lower the hormone and much more often involves intervening at later stages of the chain.